S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Sports analytics may be outnumbered when it comes to artificial intelligence
Critical asset just had biggest fall on record (Ad)
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
South Korean doctors hold massive anti-government rally over medical school recruitment plan
Critical asset just had biggest fall on record (Ad)
What to watch for as China's major political meeting of the year gets underway
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Sports analytics may be outnumbered when it comes to artificial intelligence
Critical asset just had biggest fall on record (Ad)
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
South Korean doctors hold massive anti-government rally over medical school recruitment plan
Critical asset just had biggest fall on record (Ad)
What to watch for as China's major political meeting of the year gets underway
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Sports analytics may be outnumbered when it comes to artificial intelligence
Critical asset just had biggest fall on record (Ad)
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
South Korean doctors hold massive anti-government rally over medical school recruitment plan
Critical asset just had biggest fall on record (Ad)
What to watch for as China's major political meeting of the year gets underway
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Sports analytics may be outnumbered when it comes to artificial intelligence
Critical asset just had biggest fall on record (Ad)
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
South Korean doctors hold massive anti-government rally over medical school recruitment plan
Critical asset just had biggest fall on record (Ad)
What to watch for as China's major political meeting of the year gets underway
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
OTCMKTS:ALIOF

ALIOF (ALIOF) Stock Price, News & Analysis

$278.50
0.00 (0.00%)
(As of 09/27/2022)
Today's Range
$278.50
$278.50
50-Day Range
$278.50
$278.50
52-Week Range
$138.01
$286.30
Volume
N/A
Average Volume
924 shs
Market Capitalization
$29.89 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

ALIOF stock logo

About ALIOF Stock (OTCMKTS:ALIOF)

Actelion Ltd. develops, produces and markets pharmaceutical drugs. The firm engages in research, development, manufacturing, and distribution of pharmaceutical, biological, and diagnostic products. The company was founded by Jean-Paul Clozel, Martine Clozel, Walter Fischli, André J. Müller and Thomas Widmann on December 30, 1999 and is headquartered in Allschwil, Switzerland.

ALIOF Stock Price History

ALIOF Stock News Headlines

See More Headlines
Receive ALIOF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ALIOF and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/16/2015
Today
3/03/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Medicinals & Botanicals
Sub-Industry
N/A
Current Symbol
OTCMKTS:ALIOF
CIK
N/A
Employees
N/A
Year Founded
1997

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Market Cap
$29.89 billion
Optionable
Not Optionable
Beta
N/A
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Should I Buy ALIOF Stock? ALIOF Pros and Cons Explained

These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of ALIOF was last updated on Friday, March 1, 2024 at 8:02 PM.

Pros

Here are some ways that investors could benefit from investing in ALIOF:

  • Actelion Ltd. develops, produces, and markets pharmaceutical drugs, which can lead to potential growth opportunities in the healthcare sector.
  • The company has a strong research and development focus, indicating a commitment to innovation and staying competitive in the market.
  • Recent leadership changes, including the appointment of new executives, may bring fresh perspectives and strategies to drive company growth.
  • Actelion Ltd. has a history of successful partnerships and collaborations, which could lead to further expansion and revenue generation.
  • The current stock price of ALIOF is favorable, providing a potentially attractive entry point for investors looking to capitalize on future gains.

Cons

Investors should be bearish about investing in ALIOF for these reasons:

  • While the company has a strong focus on research and development, there is also a risk of high costs associated with drug development and regulatory approvals.
  • Market competition in the pharmaceutical industry is intense, which could pose challenges for Actelion Ltd. to maintain market share and profitability.
  • Fluctuations in drug pricing regulations and healthcare policies could impact the company's revenue and profitability in the future.
  • Global economic uncertainties and geopolitical factors may affect the demand for pharmaceutical products, potentially impacting ALIOF's financial performance.
  • Investors should carefully consider the risks associated with investing in the healthcare sector, including regulatory changes and market volatility.














ALIOF Stock Analysis - Frequently Asked Questions

How have ALIOF shares performed in 2024?

ALIOF's stock was trading at $278.50 at the beginning of 2024. Since then, ALIOF shares have increased by 0.0% and is now trading at $278.50.
View the best growth stocks for 2024 here
.

How were ALIOF's earnings last quarter?

ALIOF (OTCMKTS:ALIOF) posted its quarterly earnings data on Monday, February, 16th. The company reported $0.87 earnings per share for the quarter, missing the consensus estimate of $1.09 by $0.22. The business had revenue of $501.50 million for the quarter, compared to analysts' expectations of $546.30 million.

How do I buy shares of ALIOF?

Shares of ALIOF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:ALIOF) was last updated on 3/3/2024 by MarketBeat.com Staff